Canonical activating RAS pathway mutations (HRAS, NRAS, KRAS, BRAF, RAF1, CDK4, CCND1, and NF1) were significantly more frequent in relapsed ALT-positive NB (p = 0.0013), supporting the specific impact of RAS pathway mutations on relapsed ALT-positive tumors. Here, GPT is linked to neuroblastoma.